The trademark ROFLUX was filed by Zentiva, k.s., a corporation established under the laws of the Czech Republic (the "Applicant"). The application was published for oppositions on February 25, 2020, and received undefined oppositions.
Opposition Proceedings
There are undefined Oppositions claimed against trademark.
The first opposition filed on May 25, 2020 by BIAL Portela & Cª., S.A. on Likelihood of confusion. the opponent was represented by J. PEREIRA DA CRUZ, S.A. and its proceedings were handled in English The second opposition filed on May 19, 2020 by HEXAL AKTIENGESELLSCHAFT on Likelihood of confusion. the opponent was represented by Nordemann Czychowski & Partner Rechtsanwältinnen und Rechtsanwälte mbB and its proceedings were handled in English
The application was filed in Czech, and Czech was also language of all opposition proceedings (English was selected as the second language).
The Opposition with reference B 003121956 was refused according to Article 8(1)(b) EUTMR with decision issued on February 21, 2022 by the EUIPO.
Goods And Services
The mark was filed in class 5 with following description of goods:
Medicinal preparations and substances
Pharmaceutical drugs
Pharmaceuticals
All the aforesaid goods for prevention or treatment of cardiovascular diseases and disorders, blood disorders, respiratory diseases and disorders, infection, pain and inflammation, gynaecological diseases and disorders, reproductive disorders, diseases and disorders of the musculo-skeletal system, or being sex hormones pharmaceutical preparations, anesthetics, analgesics, dermatological pharmaceutical preparations, systemic hormonal pharmaceutical preparations, antiparasitic pharmaceutical preparations, ophthalmological and otological pharmaceutical preparations, or pharmaceutical preparations for use in oncology
Dietary supplements and dietetic preparations
All the aforesaid goods excluding preparations for prevention or treatment of diseases and disorders of the alimentary tract and metabolism, preparations containing rabeprazole and preparations for prevention or treatment of peptic ulcer and gastro-esophageal reflux disease, antibacterials for systemic use, antibiotics for treatment of urinary tract infections, psychoanaleptics and antidepressants.